The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
 
José Manuel Pérez-García
Employment - MedSIR
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Pharmaceutical; Eisai; Lilly O.; Roche; Seagen
 
Manuel Ruiz-Borrego
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
 
Agostina Stradella
Consulting or Advisory Role - Novartis; Seagan
Travel, Accommodations, Expenses - Novartis; Novartis
 
Begona Bermejo
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; MSD Oncology; Novartis/Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Santiago Escrivá-de-Romaní
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Pfizer; Roche
Research Funding - Byondis (Inst); Lilly (Inst); medsir (Inst); Roche (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Lourdes Calvo Martínez
No Relationships to Disclose
 
Nuria Ribelles
No Relationships to Disclose
 
Alfonso Cortés Salgado
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Pfizer; PharmaMar
Speakers' Bureau - AstraZeneca Spain; GlaxoSmithKline; MSD; Novartis
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Pfizer
Other Relationship - ONCARE Madrid
 
Cinta Albacar
No Relationships to Disclose
 
Marco Colleoni
Research Funding - Roche (Inst)
 
Geraldine Gebhart
Consulting or Advisory Role - Roche
Research Funding - Roche (Inst)
Other Relationship - Roche (I)
 
Aleix Prat
Employment - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Kerrou Khaldoun
No Relationships to Disclose
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Serena Di Cosimo
Consulting or Advisory Role - MEDSIR; Pierre Fabre
Speakers' Bureau - AstraZeneca
Research Funding - AIRC
 
Crina Popa
Employment - MedSIR
 
Daniel Alcalá-López
Employment - MedSIR
 
Miguel Sampayo-Cordero
Consulting or Advisory Role - MedSIR
Speakers' Bureau - MedSIR
Research Funding - MedSIR
Travel, Accommodations, Expenses - MedSIR; Optimapharm
 
Antonio Llombart-Cussac
Stock and Other Ownership Interests - Initia-Research; MedSIR
Consulting or Advisory Role - Lilly O.; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Lilly O.; Merck Sharp & Dohme
Research Funding - Agendia; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Lilly O.; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche